The QualityStocks Daily Thursday, November 17th, 2022

Today's Top 3 Investment Newsletters

The Stock Dork(ELVT) $1.7900 +68.87%

QualityStocks(ABQQ) $0.0018 +63.64%

PennyStockProphet(ARDX) $1.7200 +40.98%

The QualityStocks Daily Stock List

CytomX Therapeutics (CTMX)

MarketBeat, StreetInsider, StockMarketWatch, The Street, QualityStocks, Zacks, TradersPro, TraderPower, Trades Of The Day, Top Pros' Top Picks, Short Term Wealth, Schaeffer's, FreeRealTime, Daily Trade Alert and Barchart reported earlier on CytomX Therapeutics (CTMX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CytomX Therapeutics Inc. (NASDAQ: CTMX) (FRA: 6C1) is a biopharmaceutical firm that is engaged in the development of antibody therapeutics based off of its Probody technology platform to treat cancer.

The firm has its headquarters in South San Francisco, California and was incorporated in September 2010 by Nancy E. Stagliano and Frederick W. Gluck. It operates as part of the pharmaceutical and medicine manufacturing industry and serves consumers in the U.S.

The company is party to strategic collaborations with Astellas Pharma Inc., Pfizer Inc., ImmunoGen Inc., Bristol-Myers Squibb Company, Amgen Inc. and AbbVie Ireland Unlimited Company, which entail the development of Probody therapeutics. The company’s mission is to offer patients less toxic and more effective therapies for inflammatory illnesses and severe ailments like cancer.

The enterprise’s product pipeline comprises of an anti-CTLA-4 Probody formulation dubbed BMS-986288 which is undergoing phase 1 clinical trials and is indicated for the treatment of solid tumors; a CTLA-4 Probody therapeutic known as BMS-986249 which is undergoing phase 1/2 clinical trials evaluating its efficacy in treating metastatic melanoma, and CX-2029 which is undergoing phase 2 clinical trials that evaluate its effectiveness in treating diffuse large B-cell lymphoma, gastro-esophageal and esophageal junction cancers, neck and head squamous cell carcinoma and squamous non-small cell lung cancer. This is in addition to developing CX-2009, which is indicated for breast cancer treatment.

The company, which recently announced its second quarter financial results for 2021, is focused on advancing its broad pipeline of Probody therapeutics across various cancer types and modalities. The success of these formulations will be beneficial not only to the patients who suffer from these fatal cancers but also to the company’s growth, as it’ll bring in more investors into the firm and boost the company’s growth.

CytomX Therapeutics (CTMX), closed Thursday's trading session at $1.6, up 32.2314%, on 42,465,016 volume. The average volume for the last 3 months is 129.644M and the stock's 52-week low/high is $1.17/$7.5299.

Ardelyx (ARDX)

MarketBeat, MarketClub Analysis, InvestorPlace, StockMarketWatch, Investors Alley, Schaeffer's, TradersPro, QualityStocks, Zacks,, TopPennyStockMovers, The Street, PoliticsAndMyPortfolio, TraderPower, Barchart, Trades Of The Day, Daily Stocks, Daily Trade Alert, Market Report, BUYINS.NET, Dynamic Wealth Report, Jason Bond, OTCtipReporter, Profitable Trader Authority, Street Insider, StreetInsider, Top Pros' Top Picks, TradersPro Morning and PennyStockScholar reported earlier on Ardelyx (ARDX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ardelyx Inc. (NASDAQ: ARDX) (FRA: 41X) is a biopharmaceutical firm that is engaged in the development and sale of medications for treating cardirenal and kidney ailments.

The firm has its headquarters in Fremont, California and was incorporated in 2007, on November 17th by Jean M. Frechet, Peter G. Schultz and Domonique Charmot. Prior to its name change in June 2008, the firm was known as Nteryx Inc. It operates as part of the healthcare sector, in the biotech and pharma sub-industry and serves consumers across the globe.

The company develops molecules that target receptors and transporters and modulate nutrient uptake or cause the secretion of key hormones, in order to produce a therapeutic benefit in patients. Unlike these systemic products, non-systemic products act from inside the intestines, in order to avoid possible side effects that occur with systemic exposure.

The enterprise’s pipeline comprises of a small molecule program known as RDX020, developed to treat metabolic acidosis; and a small potassium secretagogue molecule program dubbed RDX013, which is currently undergoing a phase 2 clinical trial assessing its effectiveness in treating hyperkalemia. In addition to this, the enterprise also develops a formulation known as tenapanor, which is undergoing a phase 3 clinical trial testing its effectiveness in treating hyperphosphatemia in patients with end-stage renal disease who are on dialysis. The formulation recently concluded phase 3 clinical trials evaluating its efficacy in treating irritable bowel syndrome in patients with constipation.

The company may soon receive approval from the FDA for an NDA application for it tenapanor formulation after it resolves the deficiencies observed in its review. The formulation’s success will not only boost the company’s growth but also encourage investments into the firm.

Ardelyx (ARDX), closed Thursday's trading session at $1.72, up 40.9836%, on 129,644,429 volume. The average volume for the last 3 months is 7.095M and the stock's 52-week low/high is $0.4902/$1.98.

Two Hands Corporation (TWOH)

Penny Stock General, Shiznit Stocks, QualityStocks, StockRockandRoll, Penny Stock 101, PennyStockLocks, Penny Stock Titans, Profitable Trader Authority, OTCtipReporter, Penny Picks, PennyStockScholar, Damn Good Penny Picks, Small Cap Firm, Fierce Analyst, Stock Commander, PennyStockProphet, StockWireNews, GrowthPennyStocks, Penny Pick Finders, BeatPennyStocks, StockOnion, Buzz Stocks, Epic Stock Picks, Monster Alerts, HotOTC, Wolf of Penny Stocks, Make Penny Stocks Great Again, MicroCapDaily, MassiveStockProfits, Insider Financial, InvestorSoup, Beacon Equity Research, Penny Stock Finder, ProTrader, Stock Preacher, StockHideout, StockStreetWire, Penny Stock Craze, OTCMagic, Penny Stock 106, Penny Stock Prodigy,, Explicit Penny Picks, Wealth Insider Alert and Winston Small Cap reported earlier on Two Hands Corporation (TWOH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Two Hands Corporation is a top custom application development company. Its focus is on creating a complete co-parenting solution, delivering tools that enable co-parents to better collaborate about parental responsibilities, in a clear and positive way. The Company formerly went by the name Innovative Product Opportunities, Inc. It changed its name to Two Hands Corporation in September of 2016. Founded in 2009, Two Hands Corporation has its head office in Toronto, Ontario.

The Company’s "Two Hands" web application launched in July of 2018. Two Hands’ ultimate aim is to improve the lives of families affected by divorce. Two Hands states that "Two Hands" is an ideal solution that will reduce the stress and worries of co-parenting.

Concerning its other offerings, Two Hands’ Gone App enables one to send encrypted text messages right from their phone, combining military-grade security, confidentiality, and privacy – with first-rate convenience, right at their fingertips. All text messages are asymmetrically encrypted. It is safe, with keys that only the rightful user owns. Gone App features Message Auto-Deletion after being read; no preview, one must click to view the message; and Screen Capture is disabled.

Moreover, Two Hands Corp Lab is an organic hemp based CBD (cannabidiol) cultivator located in Colombia. Two Hands Corp Lab is vertically integrated, producing from seed to wholesaler. It will distribute its high grade hemp based oil primarily through Latin America and Australia. In addition, it will expand its reach once countries allow for importation.

Two Hands Corporation has diversified. This is to meet new demand for online delivery due to the current Covid-19 Pandemic. In May of this year, the Company announced it was ready to launch the GoCart brand of grocery delivery applications in early June. Its GoCart Online Grocery Delivery set of applications will be rolled out in stages to meet the growing demand for online grocery delivery.

GOCART.CITY offers farm fresh, artisanal, and specialty grocery selections, delivered right to one’s doors. Customers can easily choose their choice of fresh produce, quality cut fruits and vegetables, and a wide variety of day-to-day grocery items.

Two Hands Corporation (TWOH), closed Thursday's trading session at $0.019, up 35.7143%, on 7,203,447 volume. The average volume for the last 3 months is 67.992M and the stock's 52-week low/high is $0.0129/$2.70.

AB International Group (ABQQ)

QualityStocks and MarketBeat reported earlier on AB International Group (ABQQ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AB International Group Corp. (OTCQB: ABQQ) is a development-stage firm that is engaged in developing a social video sharing platform and smartphone video mix application in the People’s Republic of China.

The firm has its headquarters in New York and was incorporated in 2013, on July 29th. It operates in the consumer discretionary sector under the retail-discretionary sub industry.

The enterprise offers a platform dubbed Ai Bia Quan Qiu, which provides matching services to merchants who are sourcing for actors to perform at advertising events. It also acquires and distributes music, TV show and movies. The intellectual property investment and licensing firm is also involved in the sale of used automobile vehicles to consumers in Krygyzstan.

The company has a patent license to a video synthesis and release system for mobile communications equipment and a video streaming service. Its services are distributed and marketed globally under and feature drama series, tv shows and Chinese movies whose exclusive rights have been acquired by the company. As a new and profitable revenue stream that was recently launched, the video streaming service is expected to bring in a lot of revenue.

The firm recently reported financial results for their first quarter of 2021, which show that revenue and gross profits grew by over 400% and 350% respectively, in comparison with the same period in the previous year. Their recently launched streaming service and the acquisition of more movie broadcast rights will boost investments into the firm and increase their revenue, as well as boost their popularity and extend their consumer reach.

AB International Group (ABQQ), closed Thursday's trading session at $0.0018, up 63.6364%, on 67,992,225 volume. The average volume for the last 3 months is 4,819 and the stock's 52-week low/high is $0.001/$0.0399.

Hunting PLC (HNTIF)

MarketBeat, Trades Of The Day, Daily Trade Alert and StreetInsider reported earlier on Hunting PLC (HNTIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hunting PLC (OTC: HNTIF) (LON: HTG) (FRA: 0YT) is a global energy services provider that is involved in manufacturing and distributing tools and components for the upstream oil and gas industry globally.

The firm has its headquarters in London, the United Kingdom and was incorporated in 1874. It operates as part of the oil and gas equipment and services industry, under the energy sector. The firm serves consumers around the globe.

The company operates through the Hunting Titan, North America, EMEA, Asia Pacific and Central geographical segments. The Hunting Titan segment manufactures and distributes perforating products and accessories while the EMEA segment has operations in the United Kingdom, the Netherlands, Norway, Saudi Arabia, and the United Arab Emirates. On the other hand, the Asia Pacific segment manufactures connections, accessories and OCTG supply. The company has a client base that includes many of the world's international oil and gas firms.

The enterprise manufactures premium, high-end downhole metal tools and components required for the extraction of hydrocarbons across the well construction, completion and intervention stages of the well's lifecycle. It provides perforating guns and hardware, energetics charges, and instrumentation products; and connections, oil country tubular goods, drilling tools, subsea equipment, intervention tools, and electronics. The enterprise also offers deep hole drilling and precision machining services; mud motors and drill pipe products; and well intervention services. The enterprise caters to oil and gas, aerospace, transportation, government and defense, power generation nuclear, chemical and refining industries.

The firm is well-positioned to secure market share through the protection of its intellectual property by means of trademarks and patents. This will positively influence the firm’s growth and help create value for its shareholders.

Hunting PLC (HNTIF), closed Thursday's trading session at $3.14, even for the day. The average volume for the last 3 months is 90,545 and the stock's 52-week low/high is $2.00/$4.26.

Currys PLC (DSITF)

MarketBeat, Trades Of The Day,, Daily Trade Alert and StreetInsider reported earlier on Currys PLC (DSITF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Currys PLC (OTC: DSITF) (LON: CURY) (FRA: CWB) is an electrical and telecommunications retailer and services firm that provides consumer electronics and mobile technology products and services.

The firm has its headquarters in London, the United Kingdom and was incorporated in 1884. Prior to its name change in September 2021, the firm was known as Dixons Carphone Plc. It operates as part of the specialty retail industry, under the consumer cyclical sector. The firm serves consumers in Europe.

The company operates through the Ireland and United Kingdom; Greece; and Nordics geographical segments. The Ireland and United Kingdom segment is made up of its operations in Ireland and the UK, the non-honeybee business to business operations and the Dixons Travel business. On the other hand, the Nordics segment is involved in the company’s business in Sweden, Norway, Denmark, Finland and Iceland. The Greece segment comprises of the company’s ongoing operations in Greece and Cyprus.

The enterprise provides consumer electronics in the following categories: office and computing accessories (scanners, printers, data storage, software, networking, components & upgrades); computing (including laptops, desktop PCs, netbooks & tablet PCs); audio (from surround sound to iPods, radios, MP3 players, docking & headphones); household appliances (laundry, refrigeration, small kitchen appliances, floor care); gaming (consoles and PC games & hardware); home entertainment (TV, DVD & Blu-ray); and photography (cameras, camcorders & digital photo frames). It sells its products online.

The firm is committed to growing its market share and building longer-term customer relationships, which will generate additional revenues, bolster its growth and increase the demand for its products and services.

Currys PLC (DSITF), closed Thursday's trading session at $0.94, off by 4.0816%, on 90,545 volume. The average volume for the last 3 months is 1.066M and the stock's 52-week low/high is $0.621/$1.83.

Sana Biotechnology (SANA)

Trades Of The Day, MarketBeat and Daily Trade Alert reported earlier on Sana Biotechnology (SANA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sana Biotechnology Inc. (NASDAQ: SANA) is a biotechnology firm that is focused on the creation and delivery of engineered cells as medicines.

The firm has its headquarters in Seattle, Washington and was incorporated in July 2018 by Hans Edgar Bishop, Robert Taylor Nelsen, Noubar B. Afeyan and Steven D. Harr. Prior to its name change in September 2018, the firm was known as FD Therapeutics Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company develops in-vivo and ex-vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including diabetes, oncology, cardiovascular illnesses, central nervous system (CNS) disorders, and genetic disorders, among others.

The enterprise’s product pipeline is comprised of SG221 and SG239 for the treatment of multiple myeloma; SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; and SG328 for ornithine transcarbamylase deficiency. It also develops a CD19 allogeneic T cell therapy dubbed SC291; SC255 for multiple myeloma; SG418 for sickle cell disease and beta-thalassemia; SC379 for secondary progressive multiple sclerosis, Huntington's disease and Pelizaeus-Merzbacher disease ; and SC451 for type I diabetes mellitus.

The firm recently announced its latest financial results, with its CEO noting that they remained focused on making progress across its pipeline and platforms. The success and approval of its formulations will benefit patients with the above indications while also increasing investments into the firm.

Sana Biotechnology (SANA), closed Thursday's trading session at $4.68, off by 4.4898%, on 1,071,439 volume. The average volume for the last 3 months is 200 and the stock's 52-week low/high is $3.925/$22.12.

Vobile Group (VOBIF)

We reported earlier on Vobile Group (VOBIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vobile Group Ltd. (OTCQX: VOBIF) (HKG: 3738) is an investment holding firm that is engaged in the provision of software as a service.

The firm has its headquarters in Santa Clara, California and was incorporated in 2005 by Yangbin Wang. It operates as part of the software-application industry, under the technology sector. The firm serves consumers around the globe, with a primary focus on those in Japan, the United States and Mainland China.

The company’s advanced technology solutions enable content owners to reduce infringement-related revenue loss and increase revenue growth in online video distribution. Its additional offices are located in New York, Los Angeles, Portland in Oregon, Tokyo, Hong Kong, China, London and Melbourne, Australia.

The enterprise operates the VDNA Database (VDDB), which is a comprehensive database of authorized video fingerprints, metadata and business rules from major movie studios, television networks and record labels. It also provides online video content protection and monetization services for content owners to protect their content from unauthorized use, measure the viewership of their content, and monetize their content. This is in addition to offering content protection, measurement, and management and monetization platforms, as well as pay per transaction platforms. The enterprise serves TV networks, film studios, record labels, subscription video-on-demand content aggregators, DTC service providers, sports leagues, toys and games companies, and other content owners.

The company, which recently acquired Particle Culture Technology Group, remains focused on accelerating its business growth in China. This will help extend its consumer reach and generate significant value for its shareholders.

Vobile Group (VOBIF), closed Thursday's trading session at $0.4759, even for the day. The average volume for the last 3 months is 35,024 and the stock's 52-week low/high is $0.275/$0.6168.

Plutonian Acquisition Corp. (PLTNU)

We reported earlier on Plutonian Acquisition Corp. (PLTNU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Plutonian (NASDAQ: PLTNU) recently announced the closing of its initial public offering of 5,000,000 units, each at $10.00, including an additional 750,000 units issued pursuant to the full exercise by the underwriters of the over-allotment option. The units are listed under the ticker symbol PLTNU on the Nasdaq Capital Market and began trading on Nov. 10, 2022. Each unit consists of one share of common stock, one redeemable warrant, and one right to receive one-sixth (1/6) of a share of common stock upon the consummation of an initial business combination. Each warrant entitles its holder to purchase one share of common stock, each at a price of $11.50. Once the securities comprising the units begin separate trading, the shares of common stock, warrants and rights are expected to be listed on the Nasdaq under the symbols PLTN, PLTNW and PLTNR, respectively. EF Hutton Acquisition Corp. (NASDAQ: EFHTU), division of Benchmark Investments LLC, acted as the sole book running manager for the offering.

To view the full press release, visit

About Plutonian Acquisition Corp.

The company is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company is not limited to a particular industry or geographic region for purposes of consummating an initial business combination, although it intends to focus its search for a target business on companies engaged in metaverse technologies, tourism and e-commerce related industries in the Asia-Pacific, or APAC, region. The company is led by its Chief Executive Officer, Chairman and President Wei Kwang Ng and Chief Financial Officer Ke Wang.

Plutonian Acquisition Corp. (PLTNU), closed Thursday's trading session at $10.08, even for the day, on 35,024 volume. The average volume for the last 3 months is 505,248 and the stock's 52-week low/high is $9.99/$10.10.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO)

Green Car Stocks, InvestorPlace, QualityStocks, StocksEarning, Kiplinger Today, Schaeffer's, MarketClub Analysis, StockMarketWatch, TradersPro, BUYINS.NET, Trades Of The Day, MarketBeat, The Street, Daily Trade Alert, TopPennyStockMovers, The Online Investor, VectorVest, PoliticsAndMyPortfolio, Small Cap Firm, SmallCapVoice, Eagle Financial Publications and Cabot Wealth reported earlier on ElectraMeccanica Vehicles Corp. Ltd. (SOLO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ford has recently inched closer to Tesla, which had long held the largest market share for electric vehicles, to become the second-leading electric car manufacturer in the United States. Despite the fact that many other automakers are developing a variety of attractive and entertaining vehicles, Ford is surprisingly outperforming many of those legacy automakers to rank as the second-best-selling EV company in the country.

Right now, Ford is having a good ride on the U.S. electric vehicle market and has introduced several new brands. The Mustang Mach E, which has been fully available on the market for a year, is the reason for Ford’s success since it generated excellent sales for Ford in September.

Other models from Ford include the E-Transit van, F-150 Lightning and Ford GT LM special edition. In addition to declaring plans to double production of its F-150 Lightning, the company said it would triple its manufacturing capacity at its Mexico facility.

Mustang Mach E

We begin with the Mustang Mach E, whose sales continue to soar. According to a Ford report, sales increased by at least 47.3% from November 2021 sales. Its tremendous performance shows that this model will remain a favorite of many for a long period of time. This is evident from the Ultimate EV Battle Bracket Tournament, where the model faced off against Tesla’s Model Y, and according to the respondents, the Mustang Mach E was close to winning the battle, with 49.5% of respondents preferring it against 50.5% who chose the Model Y.

F-150 Lightning

Sales of the F-150 Lightning have continued to increase since it was launched in June, and more than 8,000 units of the F-150 have been sold so far. Thanks to the electrified version, it continues to be Ford’s quickest-selling model.

E-Transit electric van

Not only have the Mach E and F-150 Lightning contributed to Ford’s success, but the E-transit van also draws customers to the company despite its slow but unstoppable improvement. Ford estimates that its van accounts for close to 90% of the market’s sales of commercial vans. It further stated that it is currently among the most popular commercial vans being sold in America. Ford reported exceptional sales of 4,387 vans, and the company expects future sales of this model to be on par with those of its other EV models, the Mach E and the F-150 Lightning.

There are also hybrid vehicles that reported a notable increase in sales, demonstrating how Ford benefited from exceptional EV sales in September, and Ford will undeniably continue to post significant sales growth in the future.

It is game on, and other startups such as ElectraMeccanica Vehicles Corp. Ltd. (NASDAQ: SOLO) have their work cut out to claim their own share of the EV market before Tesla, Ford and a few others totally dominate the nascent industry.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO), closed Thursday's trading session at $1.2, off by 1.6393%, on 505,248 volume. The average volume for the last 3 months is 340,220 and the stock's 52-week low/high is $1.01/$3.85.

Arch Resources Inc. (ARCH)

InvestorPlace, MarketBeat, Zacks, The Online Investor, QualityStocks, MarketClub Analysis, TradersPro, Kiplinger Today, The Street, Daily Wealth, Schaeffer's, StreetAuthority Daily, StreetInsider, Trades Of The Day, Barchart, Uncommon Wisdom, InvestorGuide, Investing Daily, FreeRealTime and Daily Trade Alert reported earlier on Arch Resources Inc. (ARCH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Like most developed countries, the United States is keen on cutting its carbon emissions by phasing out dirty fuels such as coal and gasoline over the next few decades. Climate change is becoming increasingly apparent,  with global warming causing extreme weather events around the world as well as droughts that are expected to cause a major food crisis.

However, transitioning from fuels such as coal won’t be cheap; developed countries have spent decades building systems that rely on fossil fuels, and it will take significant investment to develop infrastructure for renewable energy.

The U.S. has proposed a controversial plan to fund the phase-out of coal power that has proven to be extremely divisive at the recent COP27 launch. The new proposal would see North America draw funds for its green energy transition from the sale of carbon credits to companies that produce environmental pollutants.

This essentially means that companies will be able to continue producing pollution in exchange for a fee that will be used to fund America’s transition from coal. Carbon credits have hardly been popular since they were first introduced, and their popularity hasn’t grown in recent years, especially as the need for cleaner, nonpolluting sources of energy emerges.

The proposal to use carbon credits to fund the final phase-out of coal was introduced at the UN Summit by U.S. climate envoy John Kerry. He noted that fossil fuel companies would be completely locked out of the proposal but did not explain whether or not they would be prevented from buying carbon credits from the secondhand market.

Dubbed the Energy Transition Accelerator, the system is expected to be up and running by next year’s COP28, according to Kerry.

Voluntary Carbon Markets Integrity Initiative cochair Rachel Kyte said that the proposal proved to be a “massive distraction,” stating that great steps have been taken to craft rules for the carbon credit market and that the Energy Transition Accelerator was not “baked yet.”

On top of being highly divisive, the carbon credits market is barely regulated. Critics and green energy proponents argue that companies should be trying to find ways to reduce their carbon emissions instead of offsetting the carbon they emit into the environment with cheap credits.

On the other hand, UN secretary-general António Guterres was in favor of the proposal as long as it had strict safeguards. World Resources Institute president Ani Dasgupta noted that we still had insufficient mechanisms and funding levels and that a new approach was needed to step up climate change financing.

The U.S. position reflects how hard it is going to be to completely phase out coal given how limited green energy options are in terms of their availability and penetration. It is therefore likely that existing coal companies such as Arch Resources Inc. (NYSE: ARCH) will remain in business while the world works out how to make clean energy a reliable and abundant alternative to the “dirty” fuels.

Arch Resources Inc. (ARCH), closed Thursday's trading session at $151.82, up 0.663042%, on 345,188 volume. The average volume for the last 3 months is 12,850 and the stock's 52-week low/high is $73.54/$183.53.

Perseus Mining Limited (PMNXF)

MarketBeat and Money and Markets reported earlier on Perseus Mining Limited (PMNXF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Perseus Mining Limited (OTC: PMNXF) (TSE: PRU) (ASX: PRU) (LON: OTXW) (FRA: P4Q) is a mining and exploration firm that is focused on exploring for, evaluating, developing and mining gold properties in West Africa.

The firm has its headquarters in Subiaco, Australia and was incorporated in 2003. It operates as part of the gold industry, under the basic materials sector. The firm serves consumers around the globe.

The company operates through the Edikan, Sissingué, Yaouré, and Corporate & Other segments. The Edikan, Sissingué and Yaouré segments are involved in mining, mineral exploration, evaluation and development activities. On the other hand, the Corporate and Other segment is involved in investing activities and corporate management. The company conducts its mining operations in Africa and Australia.

The enterprise holds interest in Edikan Gold Mine, Sissingué Gold Mine, and Yaouré Gold Projects. The Edikan Gold Mine is a large-scale, low-grade multi open-pit operation located on the Asankrangwa Gold Belt, Ghana. The Sissingue Gold Mine and satellite deposits are situated on the Syama-Boundiali Greenstone Belt. The terrain is comprised of granitoids, flysch sediments, intermediate volcanic, and small occurrences of mafic intrusive and molasse sediments. On the other hand, the Yaoure lies within the eastern half of Boufle greenstone belt in central Cote d'Ivoire. The belt is a north-north-east-trending assemblage of Palaeoproterozoic volcanic, sedimentary and intrusive rocks of the Birimian Super group. This zone comprises a system of structures in a 300-meter-wide zone, 200 meter stratigraphically below the CMA Zone.

The firm recently released its latest financial report, which shows an increase in its gold production. It is committed to strengthening its financial position, which will positively influence its growth and revenues.

Perseus Mining Limited (PMNXF), closed Thursday's trading session at $1.415, off by 1.049%, on 12,850 volume. The average volume for the last 3 months is 4.064M and the stock's 52-week low/high is $0.8494/$1.53.

The QualityStocks Company Corner

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development andmanufacturing of rare cannabinoids and cannabinoid analogs, hasnamed Sarah Li as vice president of accounting and InMedcontroller; the change will be effective Nov. 20, 2022. Li isreplacing Brenda Edwards, who has been serving as interim chieffinancial officer for the company. Edwards joined InMed in theinterim contract role in March after the company’s CFO retired. “Weare pleased to announce this promotion of Ms. Li to her newposition as VP of Accounting and Controller,” said InMed presidentand CEO Eric A. Adams in the press release. “She is a valuedemployee who has grown in her responsibilities and overallcontribution level to the company over the past several years.Also, on behalf of the board of directors and our employees, Iwould like to thank Ms. Edwards for her hard work as interim CFO ofInMed, and we wish her all the best in her future endeavors.” Toview the full press release, visit

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.


The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Thursday's trading session at $3.84, up 1.3193%, on 4,072,205 volume. The average volume for the last 3 months is 51,933 and the stock's 52-week low/high is $2.40/$59.25.

Recent News

Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

Golden Matrix Group Inc. (NASDAQ:GMGI) (“Golden Matrix”, “GMGI” or the “Company”), a developer andlicensor of online gaming platforms, systems and gaming content,today announced its preliminary revenues for the fiscal year endingNovember 31, 2022, resulting in expected record revenues of morethan $34 million for the fiscal year ended November 31, 2022. Thisrepresents an estimated 201% improvement on revenues of $11.3million in the comparable twelve-month period ending November 31,2021. Golden Matrix acquired its 80% controlling interest inRKingsCompetitions Ltd (“Rkings”), which operates abusiness-to-consumer (B2C) Tournament Platform at the beginning ofthe fiscal year; and as a result, there were no contributions toGMGI’s overall revenues by Rkings during the prior twelve-monthperiod. Golden Matrix CEO Brian Goodman noted, however, that, “theCompany’s traditional business-to-business (B2B) gaming segmentshowed a 30% improvement in revenue growth for the twelve monthsended November 31, 2022, compared to 2021, and it currently servicesover 600 Online Casino Brands with more than 6.8 million registeredusers across all GM-X platforms.”

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.


Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Thursday's trading session at $2.445, up 3.1646%, on 51,983 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $59.25/$.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has received$150 million funding, which the company will use in part to closeon ELMS assets. According to the announcement, the company can nowfund and close on ELMS assets and complete engineering, preparationand launch of EVs. ELMS assets include a factory in Mishawaka,Indiana; all ELMS IP, which includes essential manufacturing datafor the assembly of the class 1 van and class 3 cab chassis; allinventory including finished and unfinished vehicles, part modules,component parts, raw materials and tooling; and all propertyincluding equipment, machinery, supplies, computer hardware,software, communication equipment, data networks and data storage.“We are excited to announce today that we have the funding in placeto close on the ELMS asset acquisition,” said Mullen Automotive CEOand chair David Michery in the press release. “We expect to closequickly on the ELMS transaction. This will accelerate marketintroduction of our cargo van program and provide us with criticalmanufacturing capacity at a much lower investment than previouslyexpected to supply the rest of our product portfolio. Thecompletion of this acquisition brings together the criticalenablers for our business strategy. With our Mullen, Bollinger andELMS assets, as well as our plants, we are now in a unique positionto be a leader in the new EV auto market.” To view the full pressrelease, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $0.2736, up 2.7799%, on 235,941,372 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2101/$15.90.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) today announced the appointment of Dr. Mario Tenuta as itsagricultural greenhouse gas mitigation advisor. Dr. Tenutacurrently serves as the senior industrial research chair in 4RNutrient Stewardship and is professor of applied soil ecology atthe University of Manitoba. The company also shared news about anew joint research project aimed at reducing nitrous oxide (“N2O”)emissions associated with the use of all nitrogen fertilizers,whether organic or synthetic. The project was initiated during thelast week of November 2022 and is being conducted on the11,000-acrefarm of Tracy and Curtis Hiebert, near Sperling, Manitoba, Canada.“We are committed to doing everything we can to reduce greenhousegas emissions associated with agriculture. Our patent-pendingtechnology eliminates the carbon emissions previously associatedwith the production of traditional grey ammonia. That’s a giganticstep forward. But we aren’t stopping at that. We are alsodetermined to minimize the nitrous oxide emissions associated withall nitrogen fertilizers. There is no one in Canada betterqualified than Dr. Tenuta to lead this research program for us,”said Luna Clifford, director of strategic partnerships andalliances of FuelPositive. “We suggested the project be conductedon the Hieberts’ farm since it is near the University of Manitoba.Mario and the Hieberts could not be more in sync with us regardingtheir shared desire to fight climate change while maximizing soilhealth and crop yields.” To view the full press release, visit

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Thursday's trading session at $0.11598, up 5.4364%, on 132,710 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0789/$0.201.

Recent News

Prime Harvest Inc.

The QualityStocks Daily Newsletter would like to spotlight Prime Harvest Inc.

During the recently concluded midterm elections, marijuana measureswere on the ballot in nearly two dozen California localitiesseeking to permit recreational sales to commence in thosejurisdictions. A dozen of those measures got voter approval, and an analysis of each locality revealsinteresting factors that seemed to have played a role indetermining the ballot outcome. For example, most coastal citiesare described by marijuana advocates as “cannabis deserts” becauseretail sales aren’t permitted there. It should be noted that theselocations are populated by the affluent, and this demographic seemsuncomfortable having retail stores in their backyard. However,Huntington Beach, which is located on this coastal belt, saw avoter measure approved that could result in 10 licenses formarijuana retail being issued there. Framers of future marijuanareform voter measures therefore need to pick valuable lessons fromthe 2022 midterm outcomes in different California municipalitiesand position their campaign around the human aspects so that peoplesee those ballot initiatives clearly spelling out matters of equityand social justice. These are matters that voters are passionateabout, and they were the driving forces years back when severaljurisdictions voted yes to ending prohibition and letting licensedcompanies such as Prime Harvest Inc. to operate within their boundaries.

Prime Harvest Inc., based in San Diego, California, is a technology-focused, full-service cannabis company with horizontally diversified operations spanning various segments of the cannabis value chain, from licensing acquisition and compliance management to direct-to-consumer operations. The company is leveraging a long-term strategy of investing in the growth and scale of licensed assets anchored by the power of data-driven technology to expand its footprint throughout California.

Sustainability is key to Prime Harvest’s corporate vision. The company aims to ensure that the communities it serves capture their fair share of the fruits of the industry’s growth, including financial profit, employment opportunities, environmental enrichment and impactful innovation through R&D and education.

The company’s mission is to appeal to the ethos of the cannabis consumer by setting a new operational standard emphasizing accountability, sustainability and community. With this commitment, Prime Harvest continues to work toward positively affecting millions of lives through the creation of a world-class platform that caters to strengthening the commercial cannabis pipeline.

Jaxx Cannabis

Jaxx Cannabis is the flagship brand in Prime Harvest’s portfolio. Through Jaxx Cannabis, the company aims to use technology to facilitate a true customer-centric culture while enhancing the overall craft cannabis experience. Jaxx features an expertly curated selection of premium products from some of the most respected brands in the thriving California market.

Key values serving as the foundation of Jaxx Cannabis include:

  • Creating and nurturing a welcoming culture for all
  • Unlocking the true potential of customer value
  • Being innovative in uncovering new ways to grow both the company and the industry
  • Meeting the wants and needs of consumers to promote profitability
  • Remaining accountable for the results of its operations

It is these values that differentiate Prime Harvest and Jaxx Cannabis in the California cannabis sector.

Brand Partnerships

Prime Harvest works diligently to establish strong alliances with complementary brands that are in alignment with its culture and values. Through a combination of deliberate foresight and strategic action, the company seeks to grow existing cannabis brands and continuously discover new, high-potential performers that are primed for long-term success.

These partnerships enhance Prime Harvest’s efforts to transform the world’s cannabis access and bring its consumers high-quality products that are fair for both people and the planet.


Prime Harvest remains committed to the goal of creating a more sustainable environment, now and in the future. Concern for human beings and the environment can be observed in every facet of its operations, including its ongoing R&D activities dedicated to exploring methods of reducing and repurposing waste into composite materials and exploring the potential of the hemp plant for industrial and wellness contributions.

The company is a proud member of the Community Alliance Program, a foundation that seeks to make a difference in local communities by providing financial assistance for educational programs, housing homeless veterans, creating urban farms, and holding local arts initiatives for children and adults. The program also helps explore the natural healing attributes of medical cannabis through research, development, clinical trials, and advocating for the safe access of cannabis to those in need.

Market Overview

Ongoing changes in U.S. state government policies toward cannabis are expected to cause demand for legal marijuana to surge. In addition, the number of indications for which medical marijuana is prescribed continues to increase. These factors are expected to rapidly boost legal sales of cannabis products.

Legal sales across the U.S. hit a record of $17.5 billion in 2020, marking an increase of 46% over 2019, according to Forbes. This strong growth is expected to continue. According to a Grand View Research report, the global legal marijuana market is forecast to grow at a CAGR of 26.7 percent from 2021 to 2028.

California – Prime Harvest’s home state – has consistently led the pack in terms of U.S. cannabis sales. The Motley Fool pegged cannabis spending in the Golden State at $3.8 billion in 2020, more than doubling the second state on its list.

Leadership Team

The Prime Harvest team is composed of true experts in their respective fields focused on building a world-class organization capable of driving the cannabis industry and movement forward.

E. Duane Alexander is the company’s Founder and CEO. He brings to the team more than 25 years of real-world, hands-on cannabis retail, marketing and commercial operations experience. Mr. Alexander has championed 40+ cannabis license applications throughout the western U.S. to date.

John Wilczak is the COO of Prime Harvest. He has 30+ years of executive management, strategy development & configuration experience with GE, pharmaceutical and agriculture companies. Mr. Wilczak is a Brown & Columbia MBA with vast knowledge of technology driven intellectual properties.

Andrea Jenson is the Chief Financial Officer of Prime Harvest. As CFO, she is responsible for all the company’s financial functions, including accounting, corporate finance and investor relations. Her career spans more than 20 years of varied experience in financial management, business leadership and financial strategy.

John Kazanjian is the VP of Business Development of Prime Harvest. He has worked over 40 years in business operations, brand marketing, sales and investor/lender communications. Mr. Kazanjian earned his B.S. from Rutgers University and his MBA from Harvard University.

Johann Balbuena is the Chief Marketing Officer of Prime Harvest. She has more than six years of experience in California cannabis licensing acquisition and compliance management. Ms. Balbuena has led multimedia production and content marketing efforts for the likes of the Social Club TV app, The Emerald Cup, High Times, Weedmaps and Synergy.

Recent News


Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Drug, racial and social-justice activists will be happy to knowthat House lawmakers will be discussing marijuana reform once themidterm elections draw to a close. Although the Bidenadministration was quick to act on its green-energy and electrification promises, there were plenty of valid complaints regarding theadministration’s lack of action regarding cannabis reform.President Joseph Biden recently made waves across the country whenhe announced that his administration was taking steps to begin pardoning all Americans who had simple cannabis possession offenses on theirrecords. Given that two (Missouri and Maryland) of the five statesthat had marijuana on the ballot passed those measures in themidterm election, the subcommittee discussions may be more animatedriding on those poll results. Entities such as Advanced Container Technologies Inc. (OTC: ACTX) will probably be closely following those proceedings to gauge whatthey posit for the future.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in November 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Thursday's trading session at $0.4499, even for the day, on 102 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005/$1.87.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience recently received Independent Review Boardapproval for its upcoming human clinical nicotine study, NIC-H22-1,and expects to begin dosing soon

The company hopes to evidence that processing purified nicotinewith its patented DehydraTECH(TM) drug delivery technology leads tobetter oral-tissue absorption and reduced negative experiencescompared to leading brands currently available on the market, On!and Zyn

Last year, Lexaria conducted an animal study evaluating oralnicotine absorption, NIC-A21-1, in which it evidenced that itsDehydraTECH technology was ten to twenty times faster in deliveringcomparable levels of nicotine into the bloodstream than the peak ofthe concentration-matched controls

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announcedit had received Independent Review Board (“IRB”) approval for itsplanned human clinical nicotine study, NIC-H22-1 ( According to U.S. Food and Drug Administration (“FDA”)regulations, the receipt of the IRB approval by Lexaria means thecompany has taken the necessary steps to protect the rights andwelfare of humans participating as subjects in its upcoming humanstudy (

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in November 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $2.15, off by 6.9264%, on 12,780 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$6.20.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidarsolutions, has been recognized for Vista(R)-X120 Plus, its newautomotive lidar product. VistaX-120 was named a 2023 honoree inthe Vehicle Tech & Advanced Mobility category of the CESInnovation Award program. Cepton plans on unveiling Vista-X120 Plusat CES 2023, which will be held in Las Vegas on Jan. 5-8, 2023.According to the company, the next-generation lidar productfeatures a unique combination of ultra-slim and small-form-factor,top-end performance and real-time adaptive 3D perception.Vista-X120 Plus offers the next level of perception capabilities to“see” finer objects from further away than Cepton’s previousproducts along with automotive-grade reliability, seamlessembeddability and cost efficiency. “I am thrilled that Cepton’sinnovative technology continues to be recognized at a global leveland at events such as CES,” said Cepton cofounder and CEO Dr. JunPei. “Vista-X120 Plus is designed for both today’s consumervehicles as well as the next generation — intelligent, electrifiedand software defined. As the automotive industry evolves, our lidarinnovations never cease to advance. This new product is anextension of Cepton’s vision since 2016, which is building capable,reliable and affordable lidar solutions to enable safe andautonomous transportation for everyone. We can’t wait to introduceVista-X120 Plus to our customers, partners and visitors at CES2023.” In addition, Cepton announced a collaboration with Exwayz todemonstrate a new lidar-based perception solutions for mobilerobotics applications. According to the announcement, Exwayz’splug-and-play perception software enables lidar-based 3D mapping,localization and relocalization, and object detection andclassification. Through the partnership, Cepton anticipatesenhancing its existing perception solutions and offering newpossibilities that streamline the development and demonstration oflidar-integrated robotic systems. “Cepton’s automotive-grade lidarsensors have demonstrated the quality and reliability necessary formobile robotics solutions,” said Cepton director of productmanagement, marketing and business development Henri Häfner in thepress release. “Our core lidar technology enables an optimalcombination of high performance, ruggedness and unrivaledembeddability. We are now pleased to be working with Exwayz to alsodeploy Cepton’s award-winning Nova Lidar for near-rangeapplications. Nova is designed to address perception blind spots,with its miniature size that’s ideal for smaller unmanned systems.”To view the full press releases, visit and

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Thursday's trading session at $1.52, off by 1.9355%, on 273,539 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.01/$80.16.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturingand commercializing innovative immunotherapeutic products primarilyfor the treatment of infectious diseases and autoimmune diseases.The company’s CEO Amir Reichman, as an international subject matterexpert on pharmaceutical manufacturing and supply chains, has beenconsulted by members of U.S. Congress about related topics ofinterest. In 2021, Reichman participated in meetings in Washington,D.C., and earlier this year BiondVax welcomed a congressionaldelegation to its offices and GMP biologics manufacturing facilityin Jerusalem. A Times of Israel article explains details about Congress’s interest in near-shoringthe U.S. medical supply chain. The publication notes that duringtheir visit to Israel, the Congresspeople, “met with then-primeminister Naftali Bennett, opposition leader and now presumptiveincoming premier Benjamin Netanyahu, Defense Minister Benny Gantz,and U.S. Ambassador Tom Nides, as well as Amir Reichman, CEO of theJerusalem-based BiondVax Pharmaceuticals.” To view the fullarticle, visit

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Thursday's trading session at $0.87, off by 3.3548%, on 41,170 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.5335/$3.49.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

Organ transplants were a revolution in medicine that grantedhumanity even greater control over health and disease. The firstorgan to be transplanted successfully was a kidney in 1954, followed by the first liver, pancreas and heart transplants by thelate 1960s; lung transplants followed in the 1980s. Organtransplants have become a crucial staple of medical care as theycan significantly improve quality of life and prolong the lifespanof patients. Now, researchers in Spain have made medical historyafter they successfully implanted an intestine in a 13-month-oldchild. As different companies such as Odyssey Health Inc. (OTC: ODYY) develop and bring to market cutting-edge medical devices aimed atimproving diagnostics and treatment, patients such as Emma willhave a better chance at living a normal life despite starting outwith major health challenges.

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio


Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Thursday's trading session at $0.205, off by 6.3071%, on 154,960 volume. The average volume for the last 3 months is 154,960 and the stock's 52-week low/high is $0.11/$0.64.

Recent News

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F)

The QualityStocks Daily Newsletter would like to spotlight Hillcrest Energy Technologies Ltd. (OTCQB: HLRTF).

Hillcrest (CSE: HEAT) (OTCQB: HLRTF) is a clean energy technology company whose flagship product is asingle high-efficiency inverter architecture for use throughoutelectrification ecosystems, from renewable energy generation to EVcharging and operation. “A new class of inverter technology,Hillcrest’s Silicon Carbide (‘SiC’) traction inverter technologyconverts DC (direct current) output from batteries into AC(alternating current) input used by motors. The unique designenables power applications to utilize higher switching frequenciesand realize increased traction motor performance and reliabilitywhile operating at higher power levels without sacrificingefficiency. The inverter touches all the key points EV makers areseeking, reducing battery size and weight, minimizing overallsystem complexity, and reducing costs,” a recent article reads.“Furthermore, Hillcrest in January filed a patent application for asimplified EV charging solution leveraging its inverter tech toprovide universal, backward compatible, bidirectional (“V2X”)charging capabilities. In simpler terms, this solution eliminatesthe need for EVs to require an onboard charger, allowing forfaster, anywhere charging at a wide range of power levels. Thecompany hopes to name a launch partner and for proof-of-conceptvalidation next year. Bringing this technology to market couldreshape EV charging infrastructure needs.” To view the fullarticle, visit

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) is a clean technology company based in Vancouver, British Columbia, engaged in developing high-value, high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems.

From concept to commercialization, Hillcrest invests in the development of energy solutions that power a more sustainable and electrified future. Hillcrest power inverter technology helps produce efficiencies in electrification and maximize the performance of electric systems, including electric vehicles (EV), motors and generators.

The company offers a flexible, single-inverter architecture that can be applied at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of an EV, to provide full-cycle efficiency and performance improvements.

As momentum to electrify and decarbonize energy systems accelerates, Hillcrest believes the power inverter is increasingly emerging as a key component. While system cohorts such as battery packs, PV panels and electric motors are often in the spotlight, the inverter holds the key to unlocking efficiency and performance improvements.

Hillcrest power inverter technology is:

  • REVOLUTIONARY: high-efficiency inverter technology has the potential to revolutionize how motors respond and how efficiency is gained.
  • AGILE: able to deliver and deploy high-efficiency inverter solutions purpose-designed to meet specific customer needs.
  • INNOVATIVE: technology-forward, clean-energy experts who are focused on advancing and optimizing efficient alternative energy use across all electric vehicle and charging platforms.
  • A MARKET LEADER: a next-generation technology provider to the automotive industry’s top suppliers and manufacturers.

Technology & Applications

Hillcrest’s first application for its inverter technology – a 250 kW|800V Hillcrest SiC high efficiency traction inverter – is focused on the growing EV market. Hillcrest technology eliminates traditional design trade-offs faced across the power industry – deploying higher switching frequencies has historically meant a greater increase in losses, lower system efficiency and higher heat. Through a combination of hardware and software expertise, Hillcrest enables power applications to leverage higher switching frequencies AND

  • Realize improved power system performance and reliability
  • Operate at higher power levels without compromising efficiency

The expected benefits of Hillcrest’s traction inverter have been confirmed via testing and shared in a technical white paper, published in April 2022, that confirmed the following results:

  • Significant efficiency gains – 99%-plus inverter efficiency
  • Increased power density targeting 50kW/L+
  • Significantly increased motor efficiency
  • Lower stress on mechanical and electrical parts, enhancing reliability
  • Improved thermal management

Hillcrest has also filed a patent for an enhanced powertrain solution that offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefit of the enhanced powertrain solution is the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless, and bidirectional charging across current and future power levels. Hillcrest sees this as a true EV charging game changer.

The company’s technology applies to nearly every clean energy industry segment:

  • Wind power – an inverter is deployed at a wind turbine generator to convert the AC output, with at least one additional inverter used to deliver the power to the grid/battery.
  • Solar power – an inverter is used to convert the DC output from the photovoltaic panels into the AC power that flows to the grid/battery/home.
  • Energy storage – an inverter is deployed to convert the DC output from the storage system or batteries to the AC power that flows to the grid/home/EV.
  • EV fast chargers – an inverter converts the AC input from the grid/storage system to the DC output needed to charge an EV’s battery.

Market Outlook

According to an April 2022 market analysis by Vantage Market Research (VMR), the global power inverter market is expected to reach a value of $95 billion by 2028, driven by increasing demand for EVs, energy generating wind turbines and solar-powered photovoltaic systems. That jump is forecast from an estimated $70.5 billion market value in 2021 and represents a compound annual growth rate of more than 5%.

According to the VMR report, many governments in countries around the world are supporting alternative options for efficient and nonpolluting energy generation. This has boosted demand for wind energy and solar energy systems. Hillcrest is aiming to capture a share of this future market growth across nearly every segment of the clean energy industry.

Management Team

Don Currie is the founding CEO of Hillcrest Energy Technologies. He has led the company’s successful transition from fossil fuels into clean energy technologies. Earlier in his career, he held various senior level positions, including director, officer and vice president of corporate communications with Enhanced Oil Resources Inc., an oil and gas exploration and production company based in Houston. Prior to that, he worked in other private and public ventures spanning the mining, gaming and technology sectors.

Jamie L. Hogue is the COO of Hillcrest. She brings more than two decades of progressive policy leadership, economic analysis and organizational development experience to Hillcrest. She builds collaborative processes and solutions that drive growing organizations toward a more resilient future. She previously served as the director of operations for Arizona State University’s Ten Across initiative – a compelling observatory positioned on the front lines of economic, social and climate change. She earned a master’s degree in public administration and a bachelor’s degree in economics from Arizona State University.

Ari Berger is Chief Technology Officer at Hillcrest. He brings over a decade of commercial experience with a track record of deploying new electrification technologies and go-to-market strategies. In 2015, he founded NIG Systems Ltd. in Israel, which specializes in custom high performance control systems design. Prior to this, he previously worked for Bental Industries, a leading motor manufacturer. He holds a master’s degree in system control engineering from the Technion – Israel Institute of Technology.

Raj Clair is CFO at Hillcrest. She is a CPA who began her career at Deloitte and has served in advanced finance positions in the energy and resources sector. She has been responsible for reporting, audits and internal controls, as well as working on budgeting and forecasting. She has worked with various publicly listed companies, including SEC registrants, and has both Canadian and U.S. experience. She holds a bachelor’s degree in accounting from Simon Fraser University.

Hillcrest Energy Technologies Ltd. (NASDAQ: HLRTF), closed Thursday's trading session at $0.0875, off by 5.5076%, on 1,850 volume. The average volume for the last 3 months is 1,850 and the stock's 52-week low/high is $0.072/$0.1724.

Recent News

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF)

The QualityStocks Daily Newsletter would like to spotlight Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) .

The online advertising ecosystem is transforming as governmentsworldwide ramp up regulations to rein in collection of consumers'personal data

Google's Privacy Sandbox works toward the end of third-partycookies in Chrome, giving rise to a whole new privacy-compliantidentity ecosystem

As a company driven by the evolution of data privacy and its impacton consumers and companies, Reklaim appears well-positioned tocapitalize on emerging market opportunities amid a paradigm shifthappening with new privacy laws

User privacy is taking the online space by storm as consumersbecome increasingly conscious about how their online data isharvested and used. As a result, the online advertisingarchitecture is about to transform, and companies like Reklaim (TSX.V: MYID) (OTCQB: MYIDF) appear ready to seize the market opportunity that emerges amidintensified regulatory and consumer data protection scrutiny.Reklaim (TSX.V: MYID) (OTCQB: MYIDF), the destination for consumers to access and reclaim their data,today announced the filing of Q3-2022 financial results for thethree and six months ending Sept. 30, 2022 (“Q3-2022”). Among thehighlights, the company reported a 217% increase in annual revenueto $1,642,380 from $558,342 in 2021 (“Q3-2021”), as well as a grossmargin of $101,033, reflecting an increase of 142% from the sameperiod last year. “The shift in the data market to one of privacyand compliance continues to accelerate with more and more companieslooking for a partner who can solve these issues for them,” saidReklaim CEO Neil Sweeney. “Reklaim is poised to take advantage of this trend, and webelieve privacy regulations, including the introduction of CPRA in California, will be increasingly enforced in 2023, creating aunique opportunity for Reklaim to expand its market share. Assignaled in previous quarters, we have accelerated the reduction inour cost structure while maintaining our growth rate, and we expecta similar trajectory in the coming quarters.” To view the fullpress release, visit

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) offers a privacy-compliant identity ecosystem both online ( and via a mobile app on iOS and Android in the U.S and Canada. Reklaim believes that consumers own their data and, consequently, have the right to access their online data and choose how it is used, whether for compensation or privacy. Reklaim gives consumers visibility regarding how their data is collected and compensates them for its use, all while also providing advertisers and brands with a source of data compliant with emerging privacy regulations.

The company is driven by the evolution of privacy and how it impacts consumers and companies. Reklaim sells compliant, zero-party data to Fortune 500 brands, platforms, and data companies so that they can offset the risk of non-compliance. ‘Zero-party data’ is data that a consumer proactively and intentionally shares with an organization. This contrasts with ‘third-party data,’ which organizations have collected unbeknownst to consumers for more than 20 years. Zero-party data is the most valuable data in the US$200B data market, as it provides organizations with explicit consumer opt-in vs. through an intermediary such as a data broker.

Reklaim empowers consumers to take back control of their data. The company allows consumers to visit the platform, confirm their identity, and uncover their data that has been collected and sold for years without their explicit consent. Consumers can add, edit or delete data that is associated with their profile and choose which pieces of data they would be willing to share for weekly compensation. Reklaim is the only company in the world today providing consumers with both access to their data that is circulating in the market and a guaranteed weekly paycheck. Alternatively, for users who do not want to sell their data, users can choose to protect their data and subscribe to a suite of subscription-based (SaaS) privacy tools that obfuscate the location of their device when browsing on a mobile phone and alert them when a third-party source has leaked their data or passwords.

Reklaim was founded in 2018 and is based in New York, with offices in Toronto.

Business Model

Reklaim’s primary revenue-generating operations stem from selling consented consumer data to companies and resellers that need data that is compliant with all applicable consumer privacy laws and regulations, including the California Consumer Privacy Act (CCPA). Major Fortune 500 customers and enterprise data platforms have validated Reklaim’s zero-party data and have added this data to their marketplaces and decision-making. Reklaim has sales across three core verticals: brands and agencies that buy advertising, platforms that sell data to Fortune 500 clients, and companies whose primary business is selling data to business customers.

  • Companies & Agencies that Buy Advertising – These customers use Reklaim’s compliant data to inform their media decisions in social, connected television, programmatic and other verticals. Sales cycles are short at about 30 days. Reklaim customers in this segment are Microsoft, Amgen, Bayer, UPS, and Hasbro, to name a few.
  • Platforms that Sell Data – Reklaim has integrated its zero-party data into 15 of the largest enterprise data platforms in the world. These platforms act as the ‘grocery stores’ of data, where the Fortune 500 come to make their data purchases. Reklaim’s data has been validated and added to these platforms, providing ubiquitous distribution of Reklaim data across the data ecosystem. Due to data quality verification and technical requirements, sales cycles are typically longer, about 60-90 days. Customers include LiveRamp, Transunion, Google, The Trade Desk, Lotame, and T-Mobile.
  • Data Companies that Sell Data – These customers need to purchase compliant data to continue offering data to their clients. Sales cycles often last 90-120 days, but these contracts are typically annual, have the highest value, and auto-renew. An example is Nielsen, the television measurement company.

Market Outlook

The data industry, valued at $245 billion in the U.S. and more than $400 billion globally, is being disrupted, and Reklaim is positioned to benefit from the destructive shift.

The disruption is driven by two factors: (1) technology is reducing access to core data that the industry has become dependent upon, and (2) government intervention is emerging through laws and regulations intended to protect consumer data privacy.

Over the past 20 years, the data industry has harvested and exploited consumer data without consumers’ express consent. However, the legal and regulatory environment surrounding consumer data acquisition is rapidly evolving, placing the consumer at the center of emerging privacy policies.

The European Union’s General Data Protection Regulation (GDPR) was rolled out in 2019, followed shortly by the CCPA and the California Privacy Rights Act. More recently, the Canadian Privacy Protection Act, Brazil’s General Data Protection Law, India’s Information Technology Act, and South Africa’s Protection of Personal Information have continued the trend. As a result, industries and companies currently relying on unconsented consumer data will experience a regulation-driven disruptive migration, forcing them sooner rather than later to use only fully consented data sources. This consumer data environment is driving companies to Reklaim to replace their current data providers.

While privacy policies continue to iterate to include the consumer, Big Tech, namely Apple and Google, are increasingly removing data from the market that brands and companies have relied on. Apple’s introduction of Advanced Ad Tracing (ATT) has impacted companies’ ability to track consumer behavior across applications. Facebook, in Q4 2021, was forced to accept a US$10B write down on revenue projections due to this change and is expecting a similar US$10B right down again in 2022.

Google is making similar changes, the most significant being the removal of the third-party cookie from its Chrome browser, which has a 65% market share. This third-party cookie is responsible for the tracking that websites use to monetize by tracking consumers. The removal of the Chrome cookie will put the 1.8 billion websites operating in the open web today under pressure to find a solution to replace the 65% loss in revenue.

Management Team

Neil Sweeney is Chairman and CEO of Reklaim. He has more than 20 years in the industry, with an established reputation for visionary entrepreneurship and an ability to develop technologies. Technologies Sweeney created are used by Fortune 500 brands like Coca-Cola, Lowe’s, Walmart, General Motors, Unilever, and Mondelez. They are the core component of top media demand-side platforms, including Adelphic, The Trade Desk, AppNexus, MediaMath, and Triton Media. He is a two-time finalist for Ernst & Young’s ‘Entrepreneur of the Year’ and received Deloitte’s ‘Fast 50’ award for three consecutive years for the growth of organizations he created.

Ira Levy is CFO at Reklaim. He has over 15 years of experience in a wide range of high-growth, early-stage public and private companies. Most recently, he held the roles of Corporate Controller at VIVO Cannabis Inc. (TSX: VIVO) and Senior VP/Head of Finance for start-up Honest Inc. (d/b/a Province Brands of Canada). He has also acted as an advisor for startup AI companies through the Creative Destruction Lab Program. He received his MBA in Accounting and Finance from the Schulich School of Business at York University and is a Chartered Professional Accountant.

Jake Phillips is Chief Technical Officer at Reklaim. He is a proven technology leader who excels at bridging the gap between innovation and business in dynamic environments. He has gained a breadth of industry knowledge across telco/cable, banking, and client services. His professional experience spans enterprise integration, mobility, big data, cloud operations, and data security.

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF), closed Thursday's trading session at $0.03025, off by 27.9762%, on 175,000 volume. The average volume for the last 3 months is 175,000 and the stock's 52-week low/high is $0.03025/$0.384183.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.